Imagine a future where Type 1 Diabetes (T1D) doesn't automatically mean a lifetime of insulin injections. That future might be closer than you think! Sanofi's Teizeild has just received a positive recommendation from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for use in patients with stage 2 Type 1 Diabetes. This could be a game-changer, potentially delaying the progression to stage 3, where daily insulin becomes a necessity. But here's where it gets controversial... what does this mean for the long-term management of T1D and the potential for even earlier intervention?
In essence, the CHMP has recommended Teizeild (also known as teplizumab outside the EU) for approval to delay the onset of stage 3 T1D in both adults and children, specifically those aged eight years and older who are currently in stage 2 of the disease. If approved by the EMA, Teizeild would be the first therapy of its kind in the EU to actually modify the course of T1D, rather than just treating the symptoms.
This recommendation stems from compelling data from the TN-10 study (you can dive into the details here: https://www.nejm.org/doi/full/10.1056/NEJMoa1902226; the clinical study identifier is NCT01030861, also easily searchable on clinicaltrials.gov). This Phase 2 study revealed that Teizeild significantly pushed back the onset of stage 3 T1D by approximately two years compared to a placebo. And this is the part most people miss... the study also showed that at the end of the trial, twice as many patients in the Teizeild group remained in stage 2 T1D compared to those who received the placebo (57% vs. 28%). This suggests a real potential for long-term benefit.
The safety profile observed in the TN-10 study aligned with what's been seen in previous Teizeild studies. The most common side effects were related to blood or bone marrow (specifically, temporary lymphopenia, a decrease in white blood cells) and skin-related issues like rashes.
Olivier Charmeil, Executive Vice President, General Medicines at Sanofi, expressed his enthusiasm, stating, "We are encouraged by the positive opinion in stage 2 T1D, which represents an important step toward transforming the 100-year-old treatment paradigm for autoimmune T1D. By targeting the disease at an early stage, Teizeild can help prevent the natural progression of T1D, extending the time patients can stay independent of insulin."
Teizeild is a CD3-directed monoclonal antibody. It's already approved in several countries outside the EU, including the US, the UK, China, Canada, Israel, the Kingdom of Saudi Arabia, the United Arab Emirates, and Kuwait, for delaying the onset of stage 3 T1D in eligible patients.
Interestingly, Sanofi is re-evaluating its application for Teizeild in recently diagnosed stage 3 T1D patients in the EU, suggesting a strategic shift towards earlier intervention. This begs the question: is focusing on prevention the most effective strategy for tackling T1D?
To fully appreciate the significance of this news, let's break down what autoimmune T1D actually is. It's a progressive autoimmune disease where the body's immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. This leads to an inability to regulate blood sugar levels effectively. The progression of T1D is generally divided into four stages:
- Stage 1: The autoimmune attack has begun, detectable through the presence of two or more T1D-related autoantibodies in the blood. Blood sugar levels remain normal (normoglycemia), and the stage is presymptomatic.
- Stage 2: In addition to the autoantibodies, blood sugar levels are now abnormal (dysglycemia) due to the ongoing loss of beta cells. This stage is also presymptomatic.
- Stage 3: A significant portion of beta cells have been destroyed, leading to clinical hyperglycemia (high blood sugar) and the classic symptoms of T1D, such as increased thirst, frequent urination, unexplained weight loss, blurred vision, and fatigue. This is the stage where daily insulin therapy becomes necessary.
- Stage 4: Long-standing T1D, often with chronic diabetic complications. Beta-cell function is severely diminished (reduced by up to 95%), and autoantibodies may no longer be present.
The TN-10 study was a randomized, placebo-controlled, double-blind Phase 2 trial. It aimed to assess Teizeild's effectiveness in preventing or delaying stage 3 T1D in individuals with stage 2 T1D (presence of autoantibodies and dysglycemia) who were relatives of people with T1D. The study enrolled 76 participants aged 8 to 45 (Teizeild n=44, placebo n=32), who received either Teizeild or a placebo over a 14-day period.
The study's primary endpoint was the time elapsed between randomization and the diagnosis of stage 3 T1D. Secondary endpoints included safety and tolerability.
Sanofi, the company behind Teizeild, is a research and development-driven biopharmaceutical company that leverages artificial intelligence to improve lives and drive growth. They focus on developing medicines and vaccines that address a wide range of health challenges.
Media Relations Contacts:
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léa Ubaldi| +33 6 30 19 66 46 |lea.ubaldi@sanofi.com
Investor Relations Contacts:
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Felix Lauscher | +1 908 612 7239 | felix.lauscher@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | +1 617 710 3587 | tarik.elgoutni@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li| +33 6 84 00 90 72 |yun.li3@sanofi.com
Sanofi Forward-Looking Statement: This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties that could cause actual results to differ materially. Please refer to Sanofi's filings with the SEC and the AMF for a complete discussion of these risks and uncertainties. Sanofi undertakes no obligation to update or revise any forward-looking information or statements.
All trademarks mentioned are the property of the Sanofi group.
So, what do you think? Is delaying the onset of stage 3 T1D a significant step forward, or should we be focusing on even earlier interventions and potential cures? Share your thoughts in the comments below!
